P
Philippe Terrier
Researcher at Institut Gustave Roussy
Publications - 158
Citations - 11480
Philippe Terrier is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Sarcoma & Soft tissue sarcoma. The author has an hindex of 55, co-authored 157 publications receiving 10057 citations.
Papers
More filters
Journal Article
Hibernoma, an uncommon tumor as a differential diagnosis of liposarcoma of the thigh.
TL;DR: This report presents a case of hibernoma of the thigh whose the diagnosis initially suggested that it was a mixed liposarcoma with myxoid and well differentiated components.
Journal Article
Management of recurrent soft tissue sarcoma of the retroperitoneum
Sylvie Bonvalot,Daniel Vanel,Philippe Terrier,Caroline Robert,Axel Le Cesne,Cécile Le Péchoux +5 more
TL;DR: Surgical excision of lung metastases should remain the treatment of choice, if preoperative evaluation indicates that complete clearance of the metastases is possible and complete surgery remains the cornerstone of the treatment with best results for low grade sarcomatosis.
Journal ArticleDOI
Impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the setting of competing risks.
Antoine Italiano,Axel Le Cesne,Jean Mendiboure,Jean-Yves Blay,Sophie Piperno-Neumann,Christine Chevreau,Corinne Delcambre,Nicolas Penel,Philippe Terrier,Dominique Ranchère-Vince,Marick Laé,Sophie Le Guellec,Jean-Jacques Michels,Yves Marie Robin,Sylvie Bonvalot +14 more
TL;DR: The cumulative probabilities of local (LR) and of metastatic (MR) relapse with death as a competing event and the outcomes of interest were 3369 adult patients with localized STS from January 1990 to December 2009.
Posted ContentDOI
SRF-MYOCD axis is the targetable driver of a well differentiated aggressive subtype of leiomyosarcomas
Elodie Darbo,Elodie Darbo,Elodie Darbo,Gaëlle Pérot,Lucie Darmusey,Lucie Darmusey,Sophie Le Guellec,Laura Leroy,Laëtitia Gaston,Nelly Desplat,Noémie Thébault,Candice Merle,Candice Merle,Philippe Rochaix,Thibaud Valentin,Gwenael Ferron,Christine Chevreau,Binh Bui,Eberhard Stoeckle,Dominique Ranchère-Vince,Pierre Meeus,Philippe Terrier,Sophie Piperno-Neumann,Françoise Colin,Gonzague de Pinieux,Florence Duffaud,Jean-Michel Coindre,Jean-Yves Blay,Frédéric Chibon +28 more
TL;DR: Leiomyosarcomas (LMS) are currently treated as a single entity but are now identified as a transcriptionally, genomically and clinically homogeneous subgroup of LMS, whose oncogenesis is driven by the acquisition of high differentiation through MYOCD over-expression, which confers them sensitivity toMYOCD/SRF inhibitors, which could thus become a potential therapeutic target.
Journal ArticleDOI
High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience.
Arslane Skander Rahal,Angela Cioffi,Chahinez Rahal,Julien Domont,A. Blesius,Anna Patrikidou,Sylvie Bonvalot,Cécile Le Péchoux,Philippe Terrier,Laurence Vilcot,Emilie Lanoy,Axel Le Cesne +11 more
TL;DR: Patients who progressed after 1–2 chemotherapy lines received High-dose ifosfamide (HDI) in the form of 4 g/m2 daily (over 24 hours CI) for 3 days for a total dose of 12 g/ m2; cycles were given with growth factor support and were repeated every 3 weeks.